Skip to main content

bemarituzumab

Generic: FPA144·Code: FPA144

bemarituzumab: developed by 1 company · 5 clinical trials tracked.

bemarituzumab evidence translation

What we can confirm

What it means

Source-backed records connect bemarituzumab to FPRX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could bemarituzumab → FPRX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 2 study sponsors

Related indications

Gastric or gastroesophageal junction (GEJ) cancerGastric CancerSolid Tumors
Development Pipeline (1)
CompanyPhase
FIVE PRIME THERAPEUTICS, INC. (FPRX)
Gastric or gastroesophageal junction (GEJ) cancer
Phase 3
Clinical Trials (5)

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)

NCT05325866·Phase 1/Phase 2·AMGN
Terminated

Primary endpoint: Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)

Interventionalopen260 targetStarted 2022-09Completion 2026-0150 sites · Argentina, Australia, Austria, Belgium…Amgen

A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).

NCT05322577·Phase 1/Phase 2·AMGN
Terminated

Primary endpoint: Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)

Interventionalopen72 enrolledStarted 2022-05Completion 2025-1142 sites · Japan, Singapore, South Korea, Taiwan…Amgen

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

NCT05111626·Phase 3·AMGN
Terminated

Primary endpoint: Part 1: Number of Participants Who Experienced DLTs

InterventionalRandomizeddouble515 enrolledStarted 2022-03Completion 2025-1050 sites · Argentina, Australia, United StatesAmgen

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression

NCT05052801·Phase 3·AMGN
Completed

Primary endpoint: Overall Survival

InterventionalRandomizeddouble547 enrolledStarted 2022-03Completion 2026-0450 sites · Argentina, Australia, Belgium, Brazil…Amgen

FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1

NCT03694522·Phase 2·TGTX
Completed

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizeddouble155 enrolledStarted 2018-09Completion 2022-0550 sites · Australia, Belgium, China, United StatesFive Prime Therapeutics, Inc.

Frequently asked questions

Who is developing bemarituzumab?

bemarituzumab is being developed by FIVE PRIME THERAPEUTICS, INC..

How many clinical trials involve bemarituzumab?

BioSniper tracks 5 clinical trials involving bemarituzumab.